Platform Technology

SurgiMend products are based on pioneering research and development that originated in the labs of the Massachusetts Institute of Technology (MIT). Our core understanding of the principles of tissue engineering spans over three decades. Our expertise led to the development of a platform technology that enables soft tissue repair for clinical applications that include:

We’re just getting started….

Our collagen matrix technology is able to carry agents that can play specific roles in the reconstructive process. We continue to explore the science of binding antimicrobial agents, different types of growth factors, and cells to our matrix technology, holding the future promise of better outcomes. In doing so, we plan to deliver solutions for unmet clinical needs.